CCDC106 antibody targets the coiled-coil domain-containing protein 106 (CCDC106), a conserved eukaryotic protein implicated in cellular processes such as intracellular trafficking, immune regulation, and cell cycle control. CCDC106 is localized to the Golgi apparatus and interacts with components of the NF-κB signaling pathway, modulating inflammatory responses. Studies suggest its involvement in cancer progression, particularly in lung and prostate cancers, where overexpression correlates with poor prognosis. The antibody is primarily used in research to detect CCDC106 expression via Western blotting, immunohistochemistry, and immunofluorescence. Recent investigations highlight its potential role in viral infections, as CCDC106 may interfere with host antiviral signaling. Most commercial CCDC106 antibodies are polyclonal, raised in rabbits or mice, and validated for specificity across human and murine samples. Ongoing studies aim to elucidate its molecular mechanisms and therapeutic relevance, positioning CCDC106 as a candidate biomarker or drug target. However, functional data remain limited, necessitating further exploration of its physiological and pathological roles.